1-3 of 3
Karin Potthoff
Close
Sort by
Journal Articles

Interim Results of the Observational Study Caro: Twice Weekly Carfilzomib Is a Convenient Treatment Option for Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy

Wolfgang Knauf, Andreas Ammon, Jens Uhlig, Marie Merling, Hans-Juergen Hurtz, Corinne Vannier, Holger Schulz, Norbert Marschner, Tamara Riedt, PhD, Karin Potthoff
Journal: Blood
Blood (2018) 132 (Supplement 1): 5662.
https://doi.org/10.1182/blood-2018-99-117996
Published: 2018
Journal Articles

Reduced-toxicity conditioning with fludarabine, BCNU, and melphalan in allogeneic hematopoietic cell transplantation: particular activity against advanced hematologic malignancies

Reinhard Marks, Karin Potthoff, Joachim Hahn, Gabriele Ihorst, Hartmut Bertz, Alexandros Spyridonidis, Ernst Holler, Jürgen M. Finke
Journal: Blood
Blood (2008) 112 (2): 415–425.
https://doi.org/10.1182/blood-2007-08-104745
Published: 2008
Journal Articles

Conditioning with Fludarabine, BCNU, and Melphalan in Allogeneic Stem Cell Transplantation Results in Reduced Toxixcity and High Activity Against Advanced Hematologic Malignancies.

Reinhard Marks, MD, Karin Potthoff, MD, Joachim Hahn, MD, Gabriele Ihorst, Hartmut Bertz, MD, Alexandros Spyridonidis, MD, Ernst Holler, MD, Jurgen Finke, MD
Journal: Blood
Blood (2007) 110 (11): 3066.
https://doi.org/10.1182/blood.V110.11.3066.3066
Published: 2007